European Neuropsychopharmacology
February 2017
Stephanie M Todd, Cilla Zhou, David J Clarke et al.
The evidence base for the use of medical cannabis preparations containing specific ratios of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) is limited. While there is abundant data on acute interactions between CBD and THC, few studies have assessed the impact of their repeated co-administration. We previously reported that CBD inhibited or potentiated the acute effects of THC dependent on...
Experimental and Clinical Psychopharmacology
February 2017
Kathryn R. Hefner, Mark. J. Starr
Maladaptive decision-making is a cardinal feature of drug use, contributing to ongoing use, and reflecting alterations in how drug users assess uncertain reward value. Accumulating evidence indicates the consequences of heavy marijuana use are worse for female versus male animals and humans, but research assessing sex differences in reward-related decision-making among marijuana users remains...
Pharmacology, Biochemistry, and Behavior
January 2017
Jessica S Fogel, Thomas H Kelly, Philip M Westgate et al.
Previous studies suggest that there are sex differences in endocannabinoid function and the response to exogenous cannabinoids, though data from clinical studies comparing acute cannabinoid effects in men and women under controlled laboratory conditions are limited. To further explore these potential differences, data from 30 cannabis users (N=18 M, 12 F) who completed previous...
Cannabis and Cannabinoid Research
2017
Chandni Hindocha, Tom P. Freeman, Helen Valerie Curran
42 citations
Abstract Introduction: Major gaps exist in the measurement of cannabis exposure. The accuracy of self-reported cannabis and tobacco dose per joint is poorly characterized and has never been investigated following acute cannabis/tobacco exposure. Using an innovative “Roll a Joint” paradigm, this study aims to (1) compare estimated and actual dose of cannabis and tobacco per joint at baseline and...
ERA: Education and Research Archive
2017
David Rossolatos
Cannabis use is a known risk factor for the development of psychotic disorders. Clinical and preclinical genetic studies provide growing evidence that genes related to dopamine signalling and neuroprotection, like COMT, are implicated in the cannabis-psychosis association. Considering the burden of psychosis on society, as well as increasing use of cannabis among the teenage population due to...
Journal of Addiction and Dependence
2017
John Samaan
Background/Introduction: Marijuana has been used for its psychotropic effects including enhanced relaxation and perceptual alterations. However, the use of synthetic cannabis (marijuana) leads to more frequent and drastic side effects than the typical use of regular marijuana, owing to the fact that synthetic cannabis has a shorter duration and an earlier peak of action. Despite all the...
CNS & Neurological Disorders - Drug Targets
2017
Francesco P Busardò, Manuela Pellegrini, Julia Klein et al.
Delta (9)-tetrahydrocannabinol (THC) is the main psychoactive compound in cannabis and is frequently identified in blood samples from apprehended drivers suspected for driving under the influence of drugs. Changing social norms towards cannabis and higher acceptability towards the drug emphasize the need for in-depth understanding of the acute neurocognitive and psychomotor effects caused by...
December 7, 2016
C. Jeantet
Le cannabis est la drogue illégale la plus consommée actuellement en France. Le Δ9-tétrahydrocannabinol (Δ9-THC), en tant qu’excocannabinoïde, a un impact sur le système visuel via le système endocannabinoïde. Physiologiquement, parmi les deux voies majoritairement responsables de la transmission de l’information visuelle aux stades les plus précoces, la voie magnocellulaire pourrait être la...
Schizophrenia Research: Cognition
December 1, 2016
Ashley M. Schnakenberg Martin, K. Bonfils, Beshaun J. Davis et al.
Literature on the relationship of cannabis use and cognition in schizophrenia provides the paradoxical view that cannabis use is sometimes linked with less severe impairment in neurocognition. This paper explored the possibility that this is a reflection of a dose related response between lifetime cannabis use and two forms of cognition, neurocognition and metacognition, in schizophrenia. It...
Journal of Medical Toxicology
December 2016
Milana Zaurova, Robert S Hoffman, David Vlahov et al.
Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at...